



Neuren Completes Data Collection in Phase III Glypromate[®] Trial

- Patient enrolment and follow-up of 320 target patients now complete
- Top level efficacy results on track to be released in December 2008

SYDNEY, Australia, 10 November 2008: Neuren Pharmaceuticals (ASX: NEU) today announced the completion of patient recruitment and follow-up in the first pivotal trial of its lead product, Glypromate[®].

In June, Neuren announced that efficacy could be established with 320 patients rather than 606 as initially planned. This was made possible by an observation that variance in the cognitive endpoint was lower than assumed in designing the trial. Neuren completed active recruitment and dosing of 320 patients in July, and these patients were followed up at 6 weeks and at 12 weeks after treatment. Follow-up data has now been received for all patients and this is undergoing final review for quality and completeness.

The two primary end points in the trial are change in cognitive function and change in Activities of Daily Living (ADL), from before to after surgery. Both are assessed prior to surgery and then at 6 weeks and at 12 weeks following the operation. Cognitive function is measured by a battery of mostly computerised tests developed by UK based Cognitive Drug Research Ltd. The results of all tests are combined into a single, composite score. Individual tests measure different components of cognitive function such as memory and attention. Top level efficacy results will be announced in December 2008.

Glypromate[®] is being developed to reduce cognitive impairment following cardiac surgery with cardiopulmonary bypass which affects up to 70 percent of patients at discharge. Approximately one-third of patients still exhibit cognitive impairment three months following surgery. More than one million cardiac bypass procedures are performed worldwide annually but there is no treatment approved to reduce or prevent cognitive impairment.

About Neuren

Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury and diseases and metabolic disorders. The Neuren portfolio comprises eight product families targeting markets with large unmet needs and limited competition. Neuren has three lead candidate molecules — Glypromate[®], Motiva[™] and NNZ-2566 — focused on a range of acute and chronic neurological conditions. For more information visit www.neurenpharma.com

For more information please contact: Larry Glass, Neuren, Tel: +1 301 758 2987 or Andrew Geddes T: +61 408 677 734.